Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2Lung Neoplasms 1

Interventions

Carboplatin 330Pemetrexed 266Cisplatin 234Docetaxel 195Paclitaxel 182Radiotherapy 181Erlotinib Hydrochloride 153pembrolizumab 147Gemcitabine 147Bevacizumab 125Drug Therapy 121Radiosurgery 115Nivolumab 112osimertinib 92durvalumab 88Gefitinib 67atezolizumab 63Vinorelbine 63Surgical Procedures, Operative 62Magnetic Resonance Spectroscopy 54anlotinib 42Immunotherapy 42Taxes 39Blood Specimen Collection 39Ipilimumab 38130-nm albumin-bound paclitaxel 38Specimen Handling 36Immune Checkpoint Inhibitors 35Radiation 34Albumin-Bound Paclitaxel 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Non-Small-Cell Lung × Trabedersen × Clear all
NCT06579196 2025-07-24

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1

University of Nebraska

Phase 1/2 Recruiting
45 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05935774 2023-08-25

OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer

University of Washington

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡